<div id="readability-page-1"><p>Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) is projected to issue its  Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.</p><div><p><span></span><span>Get <strong>Alpha Tau Medical</strong> alerts:</span></p></div><h2>Alpha Tau Medical Trading Down 7.3%</h2><p>NASDAQ DRTS opened at $7.07 on Wednesday. The firm has a market capitalization of $599.68 million, a price-to-earnings ratio of -13.60 and a beta of 1.02. The firm's 50 day simple moving average is $6.80 and its 200 day simple moving average is $4.97. Alpha Tau Medical has a 1 year low of $2.30 and a 1 year high of $8.60. </p><h2>Institutional Investors Weigh In On Alpha Tau Medical</h2><p>Institutional investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. bought a new position in shares of  Alpha Tau Medical during the third quarter valued at $62,000.  Bank of America Corp DE increased its holdings in  Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after purchasing an additional 21,677 shares during the period.  Wells Fargo &amp; Company MN raised its position in  Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo &amp; Company MN now owns 23,500 shares of the company's stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter.  Millennium Management LLC acquired a new position in  Alpha Tau Medical during the 3rd quarter worth about $170,000.  Finally, Mariner LLC lifted its holdings in  Alpha Tau Medical by 185.8% during the 3rd quarter. Mariner LLC now owns 123,250 shares of the company's stock worth $556,000 after buying an additional 80,129 shares during the period. 2.65% of the stock is owned by institutional investors. </p><h2>Wall Street Analysts Forecast Growth</h2><p>DRTS has been the subject of several recent analyst reports. Citigroup cut their target price on Alpha Tau Medical from $8.00 to $7.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, December 10th. HC Wainwright  restated a &#34;buy&#34; rating on shares of Alpha Tau Medical in a research report on Wednesday, December 10th. Zacks Research upgraded Alpha Tau Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Alpha Tau Medical in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $8.00.</p><p><b>Get Our Latest Analysis on Alpha Tau Medical</b></p><h2>Alpha Tau Medical Company Profile</h2> (Get Free Report)<p>Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.  </p><p>The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.</p><h2>Read More</h2><ul><li>Five stocks we like better than Alpha Tau Medical</li><li>New Copper-Rich “Kraken” Zone Discovered</li><li>America’s 1776 happening again</li><li>3 Signs You May Want to Switch Financial Advisors</li><li>Trade this between 9:30 and 10:45 am EST</li><li>Silver's squeeze is tightening - opportunity forming</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alpha Tau Medical Right Now?</h2><p>Before you consider Alpha Tau Medical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.</p><p>While Alpha Tau Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DRTS

<p>Alpha Tau Medical (NASDAQ:DRTS) is set to announce its Q4 2025 earnings on March 11, with analysts predicting a loss of $0.13 per share. The company has seen significant institutional investment, with notable increases from Bank of America and Wells Fargo. Currently, the stock has a market cap of $599.68 million and a consensus rating of "Hold" with a target price of $8.00. Alpha Tau focuses on targeted alpha-radiation therapies for solid tumors, with its lead product, Alpha DaRT, under clinical evaluation.</p>

- Alpha Tau Medical is set to release its Q4 2025 results on March 11, 2026, with analysts predicting a loss of $0.13 per share.  
- The company, focused on targeted alpha-radiation therapies for solid tumors, has experienced changes in institutional investments and varying analyst ratings, currently holding a consensus "Hold" rating with a target price of $8.00.  
- On a recent trading day, the stock decreased by 7.3%, closing at $7.07, highlighting its volatility and market interest in the medical technology sector.

Alpha Tau Medical (DRTS) Expected to Announce Quarterly Earnings on Wednesday